Merck's Frazier Promoted to CEO to Steer Merck To Post-Schering Success
This article was originally published in The Pink Sheet Daily
Executive Summary
In a widely anticipated move, Merck has named current president Ken Frazier as CEO
You may also be interested in...
Pfizer Watchers Try To Read New CEO's Next Moves
Pfizer, Inc.,'s abrupt management shake-up, announced Dec. 5, comes almost a year to the day its key drug Lipitor goes off patent. Whether the timing of the changes was a coincidence or the result of accumulating pressures, the patent expiration date of November 2011 is a marker for new CEO Ian Read and portends additional changes at the world's largest drug manufacturer.
Pfizer Watchers Try To Read New CEO's Next Moves
Pfizer, Inc.,'s abrupt management shake-up, announced Dec. 5, comes almost a year to the day its key drug Lipitor goes off patent. Whether the timing of the changes was a coincidence or the result of accumulating pressures, the patent expiration date of November 2011 is a marker for new CEO Ian Read and portends additional changes at the world's largest drug manufacturer.
Merck Powering Up In Emerging Markets Through Alliance And Pricing Strategies
As Merck looks to expand its geographic footprint in emerging markets, local players with extensive distribution networks will be the focus for partnerships, Merck Chief Strategy Officer and former Emerging Markets R&D Head Mervyn Turner told investors at the CLSA Emerging Markets Pharma Conference Dec.1 in New York